Download PDF
Am J Perinatol 1989; 6(2): 200-204
DOI: 10.1055/s-2007-999576
ORIGINAL ARTICLE

© 1989 by Thieme Medical Publishers, Inc.

Profile of an Oxytocin Antagonist, RWJ 22164 for Treatment of Preterm Labor in Laboratory Models of Uterine Contractility

K. T. Demarest1 , D. W. Hahn1 , E. Ericson1 , R. J. Capetola1 , A-R. Fuchs2 , J. L. McGuire1
  • 1R.W. Johnson Pharmaceutical Research Institute at Ortho Pharmaceutical Corporation, Raritan, New Jersey
  • 2Department of Obstetrics and Gynecology, Cornell University Medical College, New York, New York
Further Information

Publication History

Publication Date:
04 March 2008 (online)

Also available at
    Permissions and Reprints

ABSTRACT

An oxytocin antagonist, 1-deamino-[D-TYR(Oethyl)2, THR4, ORN8] oxytocin (RWJ 22164; dTVT), has recently been characterized in models of uterine contractility. Studies were undertaken to characterize the action of dTVT further on both oxytocin- and vasopressin-induced increases in uterine contractility both in vitro and in situ models and in a model of preterm labor. In these studies, dTVT was found to be a specific competitive inhibitor of both oxytocin- and vasopressin-induced contractions of both pregnant and nonpregnant guinea pig uterus in vitro. In situ, the intravenous administration of dTVT induced a dose-dependent inhibition of oxytocin- and vasopressin-induced contractions in a guinea pig model which measures uterine activity as changes in uterine perfusion pressure. Further studies demonstrated that the intravenous infusion of dTVT delays ongoing labor.